Dosing matters: DESTINY-CRC02 and the evolving treatment paradigm for HER2 positive colorectal cancer.

ABSTRACT:

SUBMITTER: Hannan LM 

PROVIDER: S-EPMC12314705 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature